Latest Ratios: P/E Ratio -5.2x · EV/EBITDA N/A · ROE -257.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $348M | $217M | $113M | $82M | $26M | $63M | $22M | $4M | $4M | $6M | $15M |
| Enterprise Value | $342M | $211M | $110M | $83M | $17M | $35M | $-13660837 | $-11931408 | $-5244634 | $1M | $-115300 |
| P/E Ratio → | -5.22 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | 2.97 |
| P/B Ratio | 13.21 | 10.07 | 5.40 | — | 3.13 | 2.25 | 0.59 | 0.24 | 0.27 | 0.82 | 0.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | -0.02 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -418.6% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | -397.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -257.7% | -257.7% | -409.5% | -869.9% | -233.0% | -101.5% | -53.0% | -96.9% | -107.1% | -78.8% | -71.4% |
| ROA | -135.9% | -135.9% | -137.3% | -120.9% | -109.3% | -75.5% | -47.8% | -81.6% | -87.6% | -56.7% | -47.0% |
| ROIC | -244.5% | -244.5% | -328.1% | — | — | -3073.7% | -660.4% | -307.7% | -215.2% | -154.0% | -446.1% |
| ROCE | -169.8% | -169.8% | -256.1% | -786.4% | -158.9% | -82.4% | -53.1% | -97.2% | -108.2% | -49.3% | -74.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | 0.69 | 0.48 | — | 1.95 | 0.53 | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.13 | — | -1.03 | -1.00 | -0.96 | -0.90 | -0.60 | -0.67 | -0.80 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -67.01 | -67.01 | -17.27 | -9.45 | -22.67 | — | — | — | — | — | — |
Net cash position: cash ($21M) exceeds total debt ($15M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 3.22 |
| Quick Ratio | 4.39 | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.77 | 2.82 | 3.22 |
| Cash Ratio | 4.01 | 4.01 | 5.14 | 0.75 | 1.14 | 9.46 | 12.22 | 5.81 | 4.47 | 2.62 | 3.01 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | 0.18 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 1.27 | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | 36.77 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $44M | $32M | $20M | $11M | $8M | $3M | $412320 | $175511 | $23972 | $13647 |
Regulatory and liquidity dependence
Based on reported figures, ACHV's P/B ratio of 12.20 reflects a market pricing that heavily discounts the firm's book value in anticipation of binary regulatory outcomes, suggesting that investors are currently valuing the company as a speculative option on cytisinicline rather than a traditional operating entity.
The lack of meaningful P/E or P/S multiples underscores the company's pre-revenue status, where traditional valuation metrics are rendered ineffective. Investors should monitor the valuation gap relative to peers, as the current pricing appears to reflect significant skepticism regarding the timeline and success of the NDA process.
As reported in financial statements, the ROIC has plummeted to -119.8% in 2026Q1, indicating that the company's aggressive R&D spending is currently failing to generate any productive return on invested capital, a trend that warrants further investigation into the sustainability of the current clinical development strategy.
The persistent negative returns on capital are a direct consequence of the company's reliance on external funding to support its sole clinical asset. This trend suggests that until the company achieves commercialization, capital efficiency will remain secondary to the primary objective of regulatory approval.
According to recent SEC filings, the current ratio has fluctuated significantly, reaching 2.62 in 2026Q1, which masks the underlying reality that the company's cash reserves are rapidly depleting against a high monthly burn rate, leaving little room for operational error or unexpected regulatory delays.
While the current ratio may appear adequate on the surface, the lack of revenue generation means that liquidity is entirely dependent on the timing of capital raises. Investors should monitor the cash-to-burn ratio closely, as the current trajectory suggests a high probability of further dilutive financing in the near term.
Based on the company's reported figures, the debt-to-equity ratio has climbed to 1.40 in 2026Q1, reflecting a shift toward debt-based financing as the firm struggles to maintain its clinical pipeline while facing significant constraints on traditional equity-based capital raising activities in the current market environment.
The increase in leverage appears to be a defensive measure to bridge the gap between clinical milestones and the next potential equity raise. This trend warrants caution, as rising debt service obligations in a pre-revenue context may further complicate the company's financial flexibility.
The current ratio is the most commonly misapplied metric for ACHV, as it obscures the company's lack of operational cash flow and its total dependence on external financing to meet short-term obligations, which is not captured by standard balance sheet liquidity assessments of clinical-stage biotechs.
Investors should instead focus on the 'cash runway' metric, which adjusts for the monthly burn rate and the timing of clinical trial payments. Relying on the current ratio alone may lead to an overestimation of the company's financial stability in the absence of a commercial revenue stream.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACHV stock.
Achieve Life Sciences, Inc.'s current P/E ratio is -5.2x. The historical average is 94.4x.
Achieve Life Sciences, Inc.'s return on equity (ROE) is -257.7%. The historical average is -75.0%.
Based on historical data, Achieve Life Sciences, Inc. is trading at a P/E of -5.2x. Compare with industry peers and growth rates for a complete picture.